398 related articles for article (PubMed ID: 33051619)
1. Sarcomatoid renal cell carcinoma: biology, natural history and management.
Blum KA; Gupta S; Tickoo SK; Chan TA; Russo P; Motzer RJ; Karam JA; Hakimi AA
Nat Rev Urol; 2020 Dec; 17(12):659-678. PubMed ID: 33051619
[TBL] [Abstract][Full Text] [Related]
2. Programmed Death Ligand 1; An Immunotarget for Renal Cell Carcinoma.
Chandrasekaran D; Sundaram S; N K; R P
Asian Pac J Cancer Prev; 2019 Oct; 20(10):2951-2957. PubMed ID: 31653140
[TBL] [Abstract][Full Text] [Related]
3. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy.
Cangiano T; Liao J; Naitoh J; Dorey F; Figlin R; Belldegrun A
J Clin Oncol; 1999 Feb; 17(2):523-8. PubMed ID: 10080595
[TBL] [Abstract][Full Text] [Related]
4. Programmed death ligand 1/indoleamine 2,3-dioxygenase 1 expression and tumor-infiltrating lymphocyte status in renal cell carcinoma with sarcomatoid changes and rhabdoid features.
Kiyozawa D; Takamatsu D; Kohashi K; Kinoshita F; Ishihara S; Toda Y; Eto M; Oda Y
Hum Pathol; 2020 Jul; 101():31-39. PubMed ID: 32360490
[TBL] [Abstract][Full Text] [Related]
5. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.
Kawakami F; Sircar K; Rodriguez-Canales J; Fellman BM; Urbauer DL; Tamboli P; Tannir NM; Jonasch E; Wistuba II; Wood CG; Karam JA
Cancer; 2017 Dec; 123(24):4823-4831. PubMed ID: 28832979
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology, biology and treatment of sarcomatoid RCC: current state of the art.
Lebacle C; Pooli A; Bessede T; Irani J; Pantuck AJ; Drakaki A
World J Urol; 2019 Jan; 37(1):115-123. PubMed ID: 29858701
[TBL] [Abstract][Full Text] [Related]
7. Impact of pathological tumour characteristics in patients with sarcomatoid renal cell carcinoma.
Shuch B; Bratslavsky G; Shih J; Vourganti S; Finley D; Castor B; Treat E; Linehan WM; Pantuck AJ; Said JW; Belldegrun AS
BJU Int; 2012 Jun; 109(11):1600-6. PubMed ID: 22221668
[TBL] [Abstract][Full Text] [Related]
8. [Clinicopathological features and prognosis of renal cell carcinoma with sarcomatoid differentiation].
Jiang Y; Su G; Yu W; Li J; Lu Q; Li Y; Zhang W
Zhonghua Zhong Liu Za Zhi; 2015 Nov; 37(11):823-6. PubMed ID: 26887511
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras.
Keskin SK; Msaouel P; Hess KR; Yu KJ; Matin SF; Sircar K; Tamboli P; Jonasch E; Wood CG; Karam JA; Tannir NM
J Urol; 2017 Sep; 198(3):530-537. PubMed ID: 28411072
[TBL] [Abstract][Full Text] [Related]
10. Sarcomatoid renal cell carcinoma: Biology and treatment advances.
Mouallem NE; Smith SC; Paul AK
Urol Oncol; 2018 Jun; 36(6):265-271. PubMed ID: 29306556
[TBL] [Abstract][Full Text] [Related]
11. The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma.
McKay RR; Bossé D; Xie W; Wankowicz SAM; Flaifel A; Brandao R; Lalani AA; Martini DJ; Wei XX; Braun DA; Van Allen E; Castellano D; De Velasco G; Wells JC; Heng DY; Fay AP; Schutz FA; Hsu J; Pal SK; Lee JL; Hsieh JJ; Harshman LC; Signoretti S; Motzer RJ; Feldman D; Choueiri TK
Cancer Immunol Res; 2018 Jul; 6(7):758-765. PubMed ID: 29748390
[TBL] [Abstract][Full Text] [Related]
12. Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma.
Fukuda T; Kamai T; Masuda A; Nukui A; Abe H; Arai K; Yoshida K
Cancer Med; 2016 Aug; 5(8):1810-20. PubMed ID: 27292320
[TBL] [Abstract][Full Text] [Related]
13. Tumor cell PD-L1 expression is a strong predictor of unfavorable prognosis in immune checkpoint therapy-naive clear cell renal cell cancer.
Möller K; Fraune C; Blessin NC; Lennartz M; Kluth M; Hube-Magg C; Lindhorst L; Dahlem R; Fisch M; Eichenauer T; Riechardt S; Simon R; Sauter G; Büscheck F; Höppner W; Matthies C; Doh O; Krech T; Marx AH; Zecha H; Rink M; Steurer S; Clauditz TS
Int Urol Nephrol; 2021 Dec; 53(12):2493-2503. PubMed ID: 33797012
[TBL] [Abstract][Full Text] [Related]
14. Grade 4 unclassified renal cell carcinoma with sarcomatoid component expressing S-100 protein. A case report with peculiar diagnostic and therapeutic implications.
Miolo G; Ash A; Buonadonna A; Lo Re G; Torrisi E; Cervo S; Santeufemia DA; Tuzi A; Canzonieri V
Cancer Biol Ther; 2014; 15(11):1439-43. PubMed ID: 25482943
[TBL] [Abstract][Full Text] [Related]
15. Limitations of preoperative biopsy in patients with metastatic renal cell carcinoma: comparison to surgical pathology in 405 cases.
Abel EJ; Carrasco A; Culp SH; Matin SF; Tamboli P; Tannir NM; Wood CG
BJU Int; 2012 Dec; 110(11):1742-6. PubMed ID: 22503066
[TBL] [Abstract][Full Text] [Related]
16. PD‑L1/PD‑1 blockade in breast cancer: The immunotherapy era (Review).
Li CJ; Lin LT; Hou MF; Chu PY
Oncol Rep; 2021 Jan; 45(1):5-12. PubMed ID: 33416128
[TBL] [Abstract][Full Text] [Related]
17. Sarcomatoid dedifferentiation in metastatic clear cell renal cell carcinoma and outcome on treatment with anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors: a retrospective analysis.
Beuselinck B; Lerut E; Wolter P; Dumez H; Berkers J; Van Poppel H; Joniau S; Oyen R; De Wever L; Strijbos M; Paridaens R; Schöffski P
Clin Genitourin Cancer; 2014 Oct; 12(5):e205-14. PubMed ID: 24861951
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors.
Chahoud J; Msaouel P; Ross JA; McCormick BZ; Bathala TK; Gao J; Horn R; Xiao L; Sircar K; Campbell MT; Shah AY; Goswami S; Zurita AJ; Jonasch E; Matin SF; Wood CG; Karam JA; Sharma P; Tannir NM
Urol Oncol; 2021 Feb; 39(2):134.e9-134.e16. PubMed ID: 33187886
[TBL] [Abstract][Full Text] [Related]
19. Chromophobe renal cell carcinoma with sarcomatoid change. A case report.
Nagashima Y; Okudela K; Osawa A; Nakamura N; Kawasaki C; Moriyama M; Nakamura N; Nakatani Y; Kitamura H; Aoki I
Pathol Res Pract; 2000; 196(9):647-51; discussion 652. PubMed ID: 10997740
[TBL] [Abstract][Full Text] [Related]
20. Review of sarcomatoid renal cell carcinoma with focus on clinical and pathobiological aspects.
Kuroda N; Toi M; Hiroi M; Enzan H
Histol Histopathol; 2003 Apr; 18(2):551-5. PubMed ID: 12647806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
